

ASTRAZENECA PLC
Form 6-K
April 04, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of (April 2019)

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b):
82- _____

AstraZeneca PLC

INDEX TO EXHIBITS

1.
Holding(s) in Company

TR-1: Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: AstraZeneca PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)
Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")
An acquisition or disposal of voting rights
An acquisition or disposal of financial instruments
An event changing the breakdown of voting rights
Other (please specify)iii: A change in the total voting rights notified by AstraZeneca PLC on 2 April 2019. X

3. Details of person subject to the notification obligationiv
Name Investor AB
City and country of registered office (if applicable) Stockholm, Sweden

4. Full name of shareholder(s) (if different from 3.)v
Name N/A
City and country of registered office (if applicable) N/A

5. Date on which the threshold was crossed or reachedvi: 2 April 2019

6. Date on which issuer notified (DD/MM/YYYY): 3 April 2019

7. Total positions of person(s) subject to the notification obligation

| | % of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments (total of 8.B 1 + 8.B 2) | Total of both in % (8.A + 8.B) | Total number of voting rights of issuervii |
|---|---|---|--------------------------------|--|
| Resulting situation on the date on which threshold was crossed or reached | 3.93% | N/A | 3.93% | 1,311,755,099 |
| Position of previous notification (if applicable) | 4.02% | N/A | 4.02% | |

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

| Class/type of shares | Number of voting rightsix | % of voting rights |
|----------------------|---------------------------|--------------------|
|----------------------|---------------------------|--------------------|

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| ISIN code (if possible) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) |
|--|---|---|---|---|
| Ordinary shares of \$0.25 each ISIN - GB0009895292 | 51,587,810 | N/A | 3.93% | N/A |
| SUBTOTAL 8. A | 51,587,810 | | 3.93% | |

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

| Type of financial instrument | Expiration date | Exercise/Conversion Period | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights |
|------------------------------|-----------------|----------------------------|--|--------------------|
| | | | | |
| SUBTOTAL 8. B 1 | | | N/A | N/A |

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

| Type of financial instrument | Expiration date | Exercise/Conversion Period | Physical or cash settlement | Number of voting rights | % of voting rights |
|------------------------------|-----------------|----------------------------|-----------------------------|-------------------------|--------------------|
| | | | | | |
| SUBTOTAL 8.B.2 | | | | N/A | N/A |

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer ^{xiii}
 Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity ^{xiv} (please add additional rows as necessary)

| Name ^{xv} | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold |
|--------------------|--|--|---|
| | | | |

10. In case of proxy voting, please identify:

| | |
|---|-----|
| Name of the proxy holder | N/A |
| The number and % of voting rights held | N/A |
| The date until which the voting rights will be held | N/A |

11. Additional information^{xvi}

This notification has been prepared using the total voting rights figure of 1,311,755,099 ordinary shares as set out in the public announcement made by AstraZeneca PLC on 2 April 2019.

| | |
|---------------------|-------------------|
| Place of completion | Stockholm, Sweden |
| Date of completion | 3 April 2019 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

| | |
|--------------------|--------------------------|
| Date: 4 April 2019 | By: /s/ Adrian Kemp |
| | Name: Adrian Kemp |
| | Title: Company Secretary |